We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
When the Trump administration came to power, one of the cornerstones of his plan was to cut regulation. One industry which has benefited dramatically from the scaling back of this regulation has been the biopharmaceutical business. With fewer restrictions on experimental drugs, biotech is having its day in the sun. One biotech enjoying a very nice run up lately is today’s Bull of the Day, ChemoCentryx .
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
The reason for the favorable Zacks Rank lies in future earnings estimate numbers. Analysts have adjusted their estimates to the upside for the current year and next year. Current year consensus has gone from a $1.18 loss up to a $1 loss. Often times, biotech companies working on new drugs have to take losses while their products go through research and development. Seeing estimates increase should help ease investor fears in the meantime.
The stock has run up aggressively since trading down at $6 to start the year. A couple of very solid earnings reports in a row, along with earnings estimates moving to the upside have helped underpin a rally into the teens. Yesterday’s aggressive selling sank the stock, serving up a potential opportunity on the pullback.
Will You Make a Fortune on the Shift to Electric Cars? Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
Image: Bigstock
Bull of the Day: ChemoCentryx (CCXI)
When the Trump administration came to power, one of the cornerstones of his plan was to cut regulation. One industry which has benefited dramatically from the scaling back of this regulation has been the biopharmaceutical business. With fewer restrictions on experimental drugs, biotech is having its day in the sun. One biotech enjoying a very nice run up lately is today’s Bull of the Day, ChemoCentryx .
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).
The reason for the favorable Zacks Rank lies in future earnings estimate numbers. Analysts have adjusted their estimates to the upside for the current year and next year. Current year consensus has gone from a $1.18 loss up to a $1 loss. Often times, biotech companies working on new drugs have to take losses while their products go through research and development. Seeing estimates increase should help ease investor fears in the meantime.
ChemoCentryx, Inc. Price and Consensus
ChemoCentryx, Inc. Price and Consensus | ChemoCentryx, Inc. Quote
The stock has run up aggressively since trading down at $6 to start the year. A couple of very solid earnings reports in a row, along with earnings estimates moving to the upside have helped underpin a rally into the teens. Yesterday’s aggressive selling sank the stock, serving up a potential opportunity on the pullback.
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>